Ignite Creation Date:
2025-12-24 @ 7:02 PM
Ignite Modification Date:
2026-01-01 @ 7:55 AM
Study NCT ID:
NCT01272557
Status:
UNKNOWN
Last Update Posted:
2014-04-01
First Post:
2011-01-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
Sponsor:
PD Dr. med. Matthias Dollinger
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SoraDox
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None